)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Eledon Pharmaceuticals (ELDN) investor relations material
Eledon Pharmaceuticals Piper Sandler 37th Annual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Piper Sandler 37th Annual Healthcare Conference summary4 Dec, 2025
Key clinical results and safety profile
Phase 2 BESTOW trial showed tegoprubart was not inferior to tacrolimus in efficacy for kidney transplant patients, with a strong safety profile.
Over 150 patients have used tegoprubart, building a robust efficacy and safety database.
Tegoprubart demonstrated some of the highest graft function seen in clinical trials, with mean eGFR of 69 vs. 66 for tacrolimus over 52 weeks.
Adverse events were similar in number and severity, but tegoprubart had fewer serious side effects such as bacteremia, hyperglycemia, new-onset diabetes, hyperkalemia, tremors, and delayed graft function.
Patients on tacrolimus experienced more post-transplant dialysis days, higher rates of hypertension, heart failure, and other complications.
Strategic development and market focus
Sufficient funding secured to operate through Q2 2027, following a recent $57.5 million financing.
Plans to approach the FDA in the first half of next year to discuss phase 3 approval pathway for kidney transplantation.
Phase 3 trial expected to launch in the second half of the year, with 200-300 patients per arm, focusing on triple endpoints for non-inferiority.
Tegoprubart development is focused on transplantation, including kidney, islet cell, xenotransplantation, and liver programs.
Collaborations ongoing in xenotransplantation with United Therapeutics and eGenesis, with upcoming studies in cardiac and kidney xeno.
Market landscape and unmet needs
Kidney transplantation is the largest segment, with about 27,000 procedures annually in the U.S. and 100,000 patients on the waitlist.
Current standard of care, tacrolimus, is a $1.5 billion market but is associated with significant toxicity and side effects.
Improving organ survival and reducing repeat transplants are key goals, as 11% of waitlisted adults need repeat procedures.
The market is highly concentrated, with 100 centers performing 80% of transplants, making it accessible for targeted commercialization.
Tegoprubart aims to address both the efficacy and safety limitations of current immunosuppressive therapies.
Tego's path for non-kidney transplant indications?
Commercial strategy against entrenched tacrolimus?
Leverage Tego's safety for FDA approval path?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Eledon Pharmaceuticals earnings date
Q4 202526 Mar, 2026
Next Eledon Pharmaceuticals earnings date
Q4 202526 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Eledon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat autoimmune diseases, organ transplantation, and neurodegenerative disorders. The company’s lead program involves developing treatments that target CD40L, a key immune system pathway involved in immune response regulation. By modulating this pathway, Eledon aims to develop therapies that prevent organ transplant rejection and treat autoimmune conditions without the need for long-term immunosuppression. The company's innovative approach seeks to address significant unmet medical needs in these therapeutic areas. The company is headquartered in Irvine, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage